70 results about "Hypoxanthine" patented technology

The invention provides a perovskite solar cell, a preparation method thereof and a photovoltaic module. The perovskite solar cell comprises a first electrode, a hole transport layer, a perovskite layer, an electron transport layer and a second electrode which are stacked in sequence. The material of the hole transport layer comprises a biomolecular material which is fixed on a self-assembly monomolecular layer material through an intermolecular force, and the biomolecular material comprises one or more of guanine, adenine, thymine, uracil, cytosine, hydroxymethylcytosine, xanthine, hypoxanthine, 6-mercaptopurine and corrin. According to the perovskite cell provided by the invention, the biomolecular material with a plurality of nitrogen heterocyclic structures and amino groups is added to generate multipoint hydrogen-bond interaction and pi-pi accumulation with the tail end of the SAM, so that the orderliness of molecular arrangement is improved, and the dipole direction and strength of the whole interface are regulated and controlled; and a coordination bond or hydrogen bond network is formed by the coordination compound and uncoordinated cations or anions in perovskite, so that interface defects are effectively passivated, and the thermal stability and the humid and hot life of a device are enhanced.

The invention belongs to the technical field of gestational diabetes diagnosis marker screening, and particularly relates to a biomarker for predicting or diagnosing gestational diabetes and application of the biomarker. The invention discloses a biomarker for predicting or diagnosing gestational diabetes mellitus, the biomarker is selected from one or more of hypoxanthine, cortisol, dihydrotachysterol and cycloleucine, and more preferably, the biomarker comprises hypoxanthine, cortisol, dihydrotachysterol, (3R, 4R)-D-ketolactone, creatine, cycloleucine and L-hydroorotic acid. The seven biomarkers disclosed by the invention can predict or diagnose gestational diabetes mellitus independently or jointly through plasma detection at the early pregnancy stage, effectively improve the early diagnosis rate of gestational diabetes mellitus and improve disease prognosis, and have clinical use and popularization values.

The present invention provides a method for producing ribose-1-phosphate that is simple and yields improved efficiency. [Solution] A method for producing ribose-1-phosphate, comprising a contact step to produce ribose-1-phosphate and hypoxanthine by contacting inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium in a reaction solution containing inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium, wherein in the contact step, the hypoxanthine is present in an amount exceeding the saturation concentration relative to the medium.

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

Methods of treating, reducing the risk of, preventing, or alleviating a symptom of inflammation or inflammatory gastrointestinal disease by administration of a modified bacterium providing purines, in particular hypoxanthine, to the mucosa of the intestine, and compositions containing modified bacteria useful in such methods.

A probiotic composition for inhibiting the onset and progression of colorectal cancer, comprises one or more of a culture supernatant of Faecalibacterium prausnitzii (Fp) cells, live Fp cells, or non-viable Fp cells，wherein the probiotic composition comprises at least one metabolite of Fp, wherein the at least one metabolite is hypoxanthine. A use of the probiotic composition or hypoxanthine for manufacturing of a medicament for inhibiting the onset and progression of colorectal cancer.

The present application relates to the field of food processing technology, and provides a method and a device for purine reduction, and an equipment and an electronic equipment and a storage medium. The method for purine reduction includes the following steps: first cooling step: performing first cooling treatment on a food material to be treated at a first preset cooling rate to reduce a temperature of the food material to be treated to a temperature below a freezing point. By performing first cooling treatment on a food material to be treated at a first preset cooling rate to reduce a temperature of the food material to be treated to a temperature below a freezing point, the activity of ATP-degrading enzyme in the food material to be treated can be rapidly inhibited, which can quickly and effectively inhibit the generation of hypoxanthine, thereby reducing the generation of hypoxanthine, reducing the risk of hyperuricemia and gout, and having little effect on the taste and quality of the food material.

The present invention provides a therapeutic drug for frailty or muscular dystrophy, and particularly for sarcopenia, and a medicinal drug for improving motor function. The present invention provides a motor function improver that contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof and additionally contains an ATP precursor substance or is used in combination with an ATP precursor substance. The ATP precursor substance is preferably inosine, inosinic acid, or hypoxanthine. This motor function improver is preferably used as a medicinal drug and is used as a therapy or preventive for frailty and sarcopenia and as a therapy or preventive for muscle wasting and muscle loss.

The application discloses a lung nodule metabolic marker and a screening method and a construction method and application of a screening model. Specifically disclosed are the application of metabolic markers and / or reagents for detecting the metabolic markers in the preparation of products for lung nodule screening; the metabolic markers include hypoxanthine, L-ornithine, decanoyl-L-carnitine, dehydroepiandrosterone sulfate and bethanidine. The application further discloses a method for constructing a lung nodule screening model. The metabolic markers and the lung nodule screening model constructed by using the metabolic markers can effectively screen out individuals with lung nodules from healthy people, have very high sensitivity and good specificity, are fast, accurate, non-invasive and non-radiation, are suitable for wide promotion, can be used as a pre-screening tool of LDCT, are used for the preliminary screening of lung nodules of a large-scale population, and have important significance for the early discovery of lung cancer and the improvement of the prognosis of patients.

The present invention discloses a use of a hypoxanthine compound in preparing a drug for treating pulmonary fibrosis and relates to the technical field of biological medicines. In the use of the hypoxanthine compound in preparing the drug for treating the pulmonary fibrosis, through pharmacological activity detection for treatment of pulmonary fibrosis with hypoxanthine compounds subjected to structural modification and transformation, the pharmacological activities of such the compounds in various animal disease models are tested and data about the activities of preventing and treating different types of pulmonary fibrosis are provided, which proves that the hypoxanthine compounds have good activities, with an effect being obviously superior to that of a positive drug Nintedanib commonly used in clinic, and that of hypoxanthine analogues A, B, C and D as well as other hypoxanthine analogues in the prior art. The use of the hypoxanthine compound in preparing the drug for treating the pulmonary fibrosis can provide a novel skeleton for screening novel compounds for preparing drugs for treating pulmonary fibrosis and lay a theoretical foundation of developing a novel lead compound.

The invention discloses a composite functional bacterial agent for regulating nucleoside substances in Luzhou-flavor liquor as well as a preparation method and application of the composite functional bacterial agent, and belongs to the technical field of liquor production. The compound functional bacterial agent is prepared from a liquid culture of pichia kudriavzevii GTY837 and a liquid culture of pichia kudriavzevii PKW194, or a liquid culture of pichia kudriavzevii GTY837 and a liquid culture of pichia kudriavzevii PKW194, or a liquid culture of pichia kudriavzevii PKW194, or a liquid culture of pichia kudriavzevii GTY837 and a liquid culture of pichia kudriavzevii PKW194. According to the composite functional bacterial agent provided by the invention, through the synergistic effect of the GTY837 and the PKW194, the content of seven nucleoside substances such as cytidine and hypoxanthine in the Luzhou-flavor liquor is effectively increased. The microbial agent solves the technical problem of unstable generation of nucleoside substances in traditional fermentation, and realizes synergistic improvement of the flavor and health attribute of Baijiu by enriching nucleoside substances with the functions of dispelling the effects of alcohol, protecting nerves and the like while enhancing the mellow feeling, delicate flavor and other sensory qualities of the Baijiu.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

The invention discloses a CHO cell culture medium additive formula and a culture method. The CHO cell culture medium additive formula can be used for an upstream stage of in-vitro CHO cell culture and can remarkably reduce the proportion of Man5 in antibody glycosylation. The additives comprise an additive G1, an additive G2 and an additive G3; the additive G1 is a mixed mother solution with the concentration of 5g / L prepared from uridine, cytidine and hypoxanthine; the additive G2 is a mixed mother solution with the concentration of 1g / L prepared from sodium selenite and cadmium sulfate; the additive G3 is a mixed mother solution with the concentration of 100g / L prepared from asparagine, glutathione and sodium pyruvate. Compared with the prior art, the serum-free culture medium for culturing CHO cells provided by the invention has the advantages of simple components, low cost, no protein and no serum. Under the condition that cell growth and expression are not affected, the Man5 proportion in antibody glycosylation can be remarkably reduced.

The present invention relates to the technical field of biomedicine and discloses use of a hypoxanthine derivative in the preparation of a drug for treating cardiomyopathy and / or myocardial fibrosis. By assaying pharmacological activities of structurally modified and altered hypoxanthine derivatives in treating cardiomyopathy and / or myocardial fibrosis, the pharmacological activities of such compounds were tested in various animal disease models, and data on activities for preventing and treating different types of cardiomyopathy and / or myocardial fibrosis were provided. It is proven that the hypoxanthine derivatives all have good activities, the effects are significantly superior to those of a clinically commonly used drug, nintedanib, and the effects are also significantly superior to those of hypoxanthine derivatives A, B, and C and other hypoxanthine derivatives in the prior art. The hypoxanthine derivative of the present invention can provide a novel skeleton for the screening of new compounds for the preparation of a drug for treating cardiomyopathy and / or myocardial fibrosis.

To provide a screening method for a human Na+ dependent hypoxanthine transporter inhibitor to be a candidate substance for an agent for treating or preventing chronic kidney disease, particularly xanthinuria.SOLUTION: The screening method includes the step for bringing a cell expressing human SLC23A3 (solute carrier family 23 member 3) gene product into contact with a test substance in the presence of hypoxanthine and sodium ions.SELECTED DRAWING: None

The embodiment of the invention discloses a primer probe combination for detecting TTV:: RARA fusion genes by a real-time fluorescent PCR method, a kit and application. According to the invention, it is found for the first time that the UTR region of TTV is a necessary element for formation and effective detection of the TTV:: RARA fusion gene, and the UTR sequence has high conservative property among different TTV strains. Based on the key characteristic, a specific detection primer is specifically designed. Wherein the upstream primer TTV:: RARA-F adopts a degenerate primer design strategy, hypoxanthine (I basic group) is introduced, the design can cover TTV strains with different genome sequences in the body of an APL patient, broad-spectrum detection of multiple TTV:: RARA fusion genes is realized, expression products of the fusion genes can be specifically recognized, the advantages of detection efficiency and accuracy are achieved, and the kit has the advantages of high specificity, high sensitivity, high sensitivity and the like. The detection period is effectively shortened and the detection accuracy is improved.

The application discloses a bird's nest peptide for inhibiting xanthine oxidase and application thereof, and belongs to the technical field of functional polypeptides. The amino acid sequence of the bird's nest peptide for inhibiting xanthine oxidase is WGLL, can chelate an active center of xanthine oxidase (XOD), and is helpful for inhibiting the activity of XOD in catalyzing conversion of xanthine or hypoxanthine. The application further provides a bird's nest peptide powder containing the bird's nest peptide for inhibiting xanthine oxidase. The bird's nest peptide powder can significantly reduce the rate of conversion of xanthine or hypoxanthine into uric acid catalyzed by XOD, has good uric acid reducing effect, can be applied to development of uric acid reducing products or various uric acid reducing products, and has high market value.

A dual-modal quantitative detection method for hypoxanthine to determine meat freshness includes the following steps: Step 1: Measuring the RGB values ​​of the color signal after the sample reaction is complete; Step 2: Measuring the temperature T of the reaction solution; Step 3: Constructing a linear equation between hypoxanthine concentration and color signal B / G or temperature T; Obtaining the color signal B / G based on a series of standard tests at different concentrations, and constructing the linear equation B / G = XC. Hx +y, where C Hx The concentration of the standard is given; based on the temperature T obtained from the testing of a series of standard concentrations, a linear equation is constructed: T = XC. Hx +y, where C Hx For the standard concentration; Step 4: Take the sample to be tested and repeat steps 1 and 2 to obtain the color signal B / G. n and temperature T n B / G n and T n Substituting the values ​​into the corresponding linear equation, the concentration of hypoxanthine in the sample is obtained. This invention employs a colorimetric-photothermal dual-modal detection method, which improves the reliability of the detection.

This invention provides an enzymatic method for synthesizing hypoxanthine, comprising the following steps: dissolving adenine in an appropriate amount of water, adding an effective amount of deaminase, incubating the reaction at 30-50°C, adjusting the pH to 6.5-7 with acid after the reaction, and filtering and washing with water to obtain hypoxanthine. This invention uses adenine as a raw material and employs a deaminase method to synthesize hypoxanthine, overcoming the shortcomings of natural raw material extraction methods, such as complex extraction processes, low yields, and high costs. Compared with other chemical synthesis methods, it produces no byproducts and has higher yields and purity, making it highly valuable for widespread application.

This invention belongs to the field of quality testing technology for traditional Chinese medicine preparations, specifically relating to a characteristic chromatogram of Commelina communis and its pharmaceutical preparations, and further disclosing the method for constructing the characteristic chromatogram and the quality testing method for Commelina communis and its pharmaceutical preparations. Using Commelina communis medicinal material and its standard decoction as the research object, this invention identified 14 common characteristic peaks and identified 5 components: Peak 1: hypoxanthine; Peak 3: adenosine; Peak 4: guanosine; Peak 8: L-tryptophan; Peak 14: isopropanol. Under these chromatographic conditions, the established characteristic chromatogram, obtained through the detection of Commelina communis medicinal material and its related preparations, shows significant characteristic components, good separation effect, and is simple to use. It can easily and quickly identify the types and quantities of chemical components contained in Commelina communis medicinal material and its related preparations (standard decoction freeze-dried powder, formula granules), providing a more comprehensive, objective, and rapid quality evaluation method for Commelina communis medicinal material and its pharmaceutical preparations.

The present application belongs to the field of microbial technology, and particularly relates to a strain for efficiently reducing the purine content of fermented squid-flavor soy sauce and application thereof. The present application successfully screens and verifies Leuconostoc mesenteroides strain NS-01. The strain NS-01 is preserved in the China General Microbiological Culture Collection Center, located at No. 1, Beichen West Road, Yard 3, Chaoyang District, Beijing, on January 9, 2026, and has a preservation number of CGMCC No. 37336. The strain is outstanding in the production of fermented squid-flavor soy sauce and the development of low-purine fermented food, can specifically degrade four types of main purines, namely, adenine, guanine, hypoxanthine and xanthine, effectively solves the problem of excessive purine in traditional squid-flavor soy sauce, and provides a core strain for the industrialization of low-purine seafood soy sauce.

This invention provides a kit for the simultaneous detection of nine flavor nucleotides in livestock and poultry products. The flavor nucleotides are cytidine monophosphate, uridine monophosphate, guanylic acid, inosine monophosphate, adenosine monophosphate, hypoxanthine, inosine, adenosine diphosphate, and adenosine triphosphate. The kit includes: a high-concentration extraction reagent, a standard curve solution, a high-concentration phosphate buffer solution, pH adjustment solution A, and pH adjustment solution B. The high-concentration extraction reagent is perchloric acid; the standard curve solution is a mixed solution of the nine flavor nucleotides; the high-concentration phosphate buffer solution is a solution of potassium dihydrogen phosphate and dipotassium hydrogen phosphate; pH adjustment solution A is sodium hydroxide; and pH adjustment solution B is phosphate. This invention also provides a method for the simultaneous detection of the nine flavor nucleotides using the above kit. This invention enables the simultaneous determination of the content of nine flavor nucleotides in livestock and poultry products. The method is simple, rapid, accurate, and sensitive, and can be used for batch determination, showing good prospects for practical application.

The invention discloses a preparation method of threose nucleic acid based on a self-pairing primer template. The method comprises the following operation steps: synthesizing a hairpin-shaped DNA template modified by biotin and hypoxanthine, and carrying out annealing treatment to realize template self-pairing; preparing a TNA sequence in a reaction system compatible with TNA extension and TNA cutting by taking the self-pairing DNA hairpin as a template; the TNA product and the template are separated through the magnetic beads, and the DNA template combined with the magnetic beads is recycled, so that the TNA product is recycled in multiple rounds of reactions, and the target TNA product is prepared in batches; the molecular weight of the product is detected through electrospray ionization mass spectrometry, and the prepared TNA is determined as an expected product. The invention provides a method for rapidly synthesizing a large amount of TNA sequences, the preparation period of TNA is shortened, and technical support is provided for application of TNA in the fields of biotechnology and biomedicine.

The application belongs to the field of biological detection, and particularly relates to a preparation method of a capture magnetic bead. More particularly, the application relates to a preparation method of a bispecific probe capture magnetic bead. The application provides a preparation method of a bispecific probe capture magnetic bead, which comprises the following steps: coupling a capture magnetic bead with a bispecific probe, wherein a hypoxanthine is introduced into a 5' end 15bp-25bp region of the bispecific probe; and the length of the bispecific probe is 20-70 bp. The magnetic bead of the application can better capture a target fragment, ensure the stability of the capture, and has higher sensitivity. For low-concentration nucleic acids in complex sample types, the detection rate can be significantly improved, and the false capture caused by mismatches can be effectively reduced.

The present application relates to the biomedical technology field, and particularly to a blood biomarker for early coronary heart disease diagnosis, and a screening method and application thereof.The blood biomarker comprises blood clinical indicators and plasma metabolome characteristics, the blood clinical indicators comprise direct bilirubin, aspartate aminotransferase and high-density lipoprotein, and the plasma metabolome characteristics comprise pyroglutamic acid, N-formyl-L-methionine, hypoxanthine, pinobetsin and L-valyl-alanine.The present application not only uses plasma metabolome characteristics, but also incorporates blood clinical indicators through blood routine and blood biochemical detection, compared with other methods, more comprehensively reflects the physiological and pathological state of the body, reduces the possibility of result deviation, and therefore adopts multi-dimensional blood biomarkers, which can more accurately predict the risk of early coronary heart disease.In addition, the adoption of multi-dimensional blood biomarkers can also improve the specificity and sensitivity of screening and diagnosis of early coronary heart disease.

The present invention relates to the technical field of biomedicine and discloses use of a hypoxanthine derivative in the preparation of a drug for treating renal fibrosis and / or kidney disease. By assaying pharmacological activities of structurally modified and altered hypoxanthine derivatives for treating renal fibrosis and / or kidney disease, the pharmacological activities of such compounds were tested in animal disease models, and data on activities for preventing and treating renal fibrosis and / or kidney disease were provided. It is proven that the hypoxanthine derivatives have good activities, and the effects are significantly superior to those of clinically commonly used positive drugs nintedanib and losartan, and the effects are also significantly superior to those of hypoxanthine derivatives A, B, and C and other hypoxanthine derivatives in the prior art. The hypoxanthine derivative of the present invention can provide a novel skeleton for the screening of novel compounds for the preparation of a drug for treating renal fibrosis and / or kidney disease.

The invention relates to a deer sinew extract as well as a preparation method and application thereof, and belongs to the technical field of extraction of effective components of traditional Chinese medicinal materials. The invention relates to a preparation method of a deer sinew extract, which comprises the following steps: processing dry deer sinew at high temperature, crushing, sieving with a 20-100-mesh sieve to obtain deer sinew powder, extracting for 2-10 days by taking an ethanol water solution as a solvent according to a material-liquid ratio of 1: 80 g / mL, extracting once to obtain a deer sinew extracting solution, and carrying out rotary evaporation concentration and drying to obtain the deer sinew extract. The preparation process disclosed by the invention is efficient, simple and convenient, two main active ingredients of uracil and hypoxanthine can be efficiently obtained under the process conditions disclosed by the invention, and a wide application prospect is provided for further development and utilization of the deer sinew.

The invention relates to a preparation method of electronic grade hypoxanthine, which comprises the following steps: taking a hypoxanthine crude product synthesized by an enzymic method as a raw material, mixing the hypoxanthine crude product with high-purity water at the temperature of 30-60 DEG C, adjusting the pH value to 7-9, adding 0.1%-2% of neutral or alkaline protease to hydrolyze protein to react for 0.5-3 hours, cooling to 5-30 DEG C, and performing suction filtration to obtain the electronic grade hypoxanthine. Dissolving the wet product with an alkaline aqueous solution at 50-80 DEG C, removing impurities with activated carbon, performing hot filtration, adjusting the pH value of the filtrate to 6.5-7.5 with electronic-grade acid, cooling to 5-30 DEG C, crystallizing, performing suction filtration, washing the wet product with purified water for 3-5 times, and drying to obtain the product. Organic impurities, metal ions and environmental particles are systematically removed, and finally the ultra-high-purity electronic-grade hypoxanthine is prepared. The chemical purity of the prepared product is larger than or equal to 99.99%, the total metal ion content is smaller than or equal to 100 ppb, the moisture content is smaller than or equal to 0.1%, and the product has the advantages of being concentrated in particle size distribution and uniform in crystal form and completely meets the harsh requirements of OLED and other high-end photoelectric devices for key organic materials.

The application belongs to the technical field of screening of diagnostic markers for gestational diabetes, and particularly relates to a biomarker for predicting or diagnosing gestational diabetes and application thereof. The application discloses a biomarker for predicting or diagnosing gestational diabetes, wherein the biomarker is selected from one or more of hypoxanthine, cortisol, dihydrostercorol and cycloleucine, and more preferably comprises hypoxanthine, cortisol, dihydrostercorol, (3R, 4R)-D-erythrulose, creatine, cycloleucine and L-hydroxyproline. The seven biomarkers disclosed in the application can be used alone or in combination to predict or diagnose gestational diabetes in the early stage of pregnancy through plasma detection, effectively improve the early diagnosis rate of gestational diabetes, improve the prognosis of the disease, and have clinical use and promotion value.

A method for preparing and using an organic matter extractant in wastewater, comprising: 1) reacting hypoxanthine I with phosphorus oxychloride to obtain a chloro product II, then condensing the chloro product II with 5-(2-acetyloxyethyl)tetrahydrofuran-2,3,4-triyl triacetate to obtain compound III, and then subjecting the compound III to ammonolysis to obtain compound IV; 2) adding glycerol distearate and phosphorus oxychloride to a mixed solution of tetrahydrofuran and triethylamine to react to generate a phosphoryl chloride intermediate V; 3) hydrolyzing and acidifying the compound IV and the intermediate V in a mixed solution of tetrahydrofuran and triethylamine to obtain an extractant adenosine phosphate glycerol distearate VI; and 4) mechanically mixing the extractant adenosine phosphate glycerol distearate VI and aviation kerosene to obtain an organic matter extractant product in wastewater. The organic matter extractant in wastewater of the present application mainly uses adenosine phosphate ester compounds and related derivatives as a main extractant, extracts and separates various organic matters in wastewater, has a high removal rate of organic matters, and has a high recovery rate of the extractant.